

July 7, 2014 For Immediate Release

TeraBAT, Inc. Announces the Issuance of its Licensed Patent

BOULDER, CO. – The University of Massachusetts announced, "Dr. Eyal Gerecht, co-founder and CEO of *TeraBAT, Inc.*, was awarded U.S. Patent No. 8,748,822, dated June 10, 2014, entitled *Chirp-Pulse Terahertz Spectroscopy*". This patent is based on a technology breakthrough utilizing terahertz waves as a method for the detection of Volatile Organic Compounds (VOCs) in a gaseous state. The issued patent includes thirty individual claims offering powerful protection for the utilization of this important tool in multiple fields of application including healthcare, environmental monitoring, biowarfare detection and industrial safety. This technology is exclusively licensed to *TeraBAT, Inc.* from the University of Massachusetts and the National Institute of Standards and Technology (NIST). The Company, located in the HEI Inc. Boulder, Colorado facilities, is aggressively pursuing the development of the technology as a 510(k) medical device for human breath analysis for multiple disease states requiring immediate attention.

TeraBAT, Inc. is working to commercialize the technology to rapidly detect biomarkers in exhaled breath that are indicators of acute and chronic diseases. In a hospital or clinic, a health care provider would be able to initiate treatment without delay and continuously monitor the disease's state from the biomolecules present in the patient's breath. The Company plans that the non-invasive point-of-care platform will replace many of today's laboratory based diagnostics with more direct tests beside the patient, resulting in positive treatment and health as well as economic outcomes.

Mr. Jack Wheeler, Colorado serial entrepreneur in clinical diagnostics and Chief Business Development Officer at *TeraBAT, Inc.* says, "Gerecht's exciting patented technology will transform the field of medical diagnostics. Terahertz detection will offer immediate and "Point of Care" insights relating to the patients condition for both diagnostic and disease monitoring purposes."

"Having worked alongside this exciting company over the past year, I have been impressed with both their technology and management experience, each necessary to launch this breakthrough breath analysis technology. We are pleased to have the opportunity to support this medical device company and look forward to offering our expertise in furthering its development and a successful journey through the FDA and market approval." stated Mr. Mark Thomas, CEO of HEI.

About TeraBAT, Inc.:

TeraBAT, Inc. is a Colorado-based company developing a disruptive detection platform based on terawaves technologies that will revolutionize disease diagnosis and patient care. Its novel, real time detection platform will be able to identify biomolecules present in exhaled breath that are indicative of a disease state. Rapid diagnosis of both chronic and acute disease states via breath analysis will allow immediate and correct patient treatment and care.

About UMass Amherst:

Founded in 1863, the University of Massachusetts Amherst is a distinguished national research university and the flagship of the five-campus UMass system, enrolling more than 27,500 students in 94 undergraduate more than 70 graduate-level programs. UMass Amherst had \$137.4 million in sponsored research in fiscal 2009 and has an economic impact of \$1.43 billion in Massachusetts.



About NIST:

Founded in 1901, NIST is a non-regulatory federal agency within the U.S. Department of Commerce. NIST's mission is to promote U.S. innovation and industrial competitiveness by advancing measurement science, standards, and technology in ways that enhance economic security and improve our quality of life. The agency operates in two locations: Gaithersburg, Md., and Boulder, CO. NIST employs about 3,000 scientists, engineers, technicians, and support and administrative personnel. NIST also hosts about 2,700 associates from academia, industry, and other government agencies, who collaborate with NIST staff and access user facilities.

About HEI, Inc.:

HEI, Inc. Advanced Medical Division is a Medical Device manufacturing operation providing contract manufacturing and depot repair services for Class II and Class III medical devices, transitional manufacturing services, and support in design, development, verification, and validation of hardware, software, and user interfaces for numerous types of medical devices and applications.